Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.

Researchers from Vanderbilt’s Division of Nephrology and Hypertension have identified an under-studied characteristic that may have a protective effect on end-stage kidney disease (ESKD) risk among vulnerable populations.

An FDA-approved medication enhances the function of T regulatory cells (Treg), a class of immune cells that restrains the immune response, Vanderbilt investigators have discovered.

Distinct cancer-associated fibroblasts in the prostate tumor microenvironment may influence tumor progression and could point to new therapeutic targets.

In HIV-positive individuals with diabetes, immune cells in fat are more proinflammatory and cytotoxic and may represent a therapeutic target for diabetes.

The U.S. Preventive Services Task Force (USPSTF) has formally recommended two changes that will nearly double the number of people eligible for lung cancer screening by lowering the age from 55 to 50 and reducing the number of smoking history pack years from 30 to 20.

Christine Lovly, MD, PhD, associate professor of Medicine in the Division of Hematology and Oncology and Ingram Professor of Cancer Research, is one of two inaugural recipients of the EGFR Resisters/LUNGevity Lung Cancer Research Award.